Nordicus Partners acquires 100% of Bio-Convert ApS for 12M restricted shares

Nordicus Partners Corp

Acquired 100% of Danish clinical-stage biopharma Bio-Convert ApS on Nov 12, 2024.
Consideration: 12 million restricted common shares (OTCQB: NORD) issued to sellers.
Bio-Convert is developing a drug for oral leukoplakia, a potentially malignant disorder.
Nordicus previously acquired 95% of Orocidin A/S in May 2024, adding periodontitis therapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.